Skip to Content

Novel oral agent with promising result as second-line treatment option for patients with T-Cell Lymphoma

Tolinapant, a novel oral non-peptidomimetic, small-molecule antagonist of cellular/X-linked inhibitors of apoptosis proteins could be a meaningful treatment option for patients with Peripheral T-cell lymphoma (PTCL) and Cutaneous T-cell lymphoma (CTCL) when first-line therapy has failed. In this MEDtalk Jean Marie Michot shares the highlights from the new data from ASTX660 trial presented at EHA 2022 including a promising, favorable, and manageable safety profile.

Jean-Marie Michot

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top